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Introduction: Survival of ALK-rearranged NSCLC patients has dramatically improved
by the use of multiple ALK-tyrosine kinase inhibitors (ALK-TKI). However, still little is
known about the impact of drug sequencing and clinical features on survival in a
real-world setting.
Methods: Patients with stage IV ALK-rearranged NSCLC treated at six centers in
Switzerland and Italy were identified and standard clinical variables collected. OS curves
were constructed using the Kaplan–Meier method and compared with the log-rank test.
Multivariate Cox proportional hazard analysis was applied to determine the correlations
between clinical features and OS. In four patients, biopsies were subjected to NGS.
Results: One-hundred and twenty-one patients with stage IV ALK-rearranged NSCLC
diagnosed between 2011 and 2016 were included. With a median follow-up time of
39.5 months, the median OS from diagnosis of stage IV disease was 48.0 months.
First-line treatment consisted of an ALK-TKI in 24% of patients, with crizotinib in 83%
of them. Chemotherapy as first-line treatment did not influence OS (p = 0.955). The use
of more than one ALK-TKI line positively correlated with OS (p = 0.016), as well as the
use of alectinib or lorlatinib in any treatment line, as compared to the use of crizotinib ±
ceritinib (p = 0.022). A never smoking history was an independent prognostic factor for
OS (p = 0.032). Moreover, treatment with alectinib significantly improved OS.
Conclusions: Targeted treatment for ALK-positive NSCLC patients lead to prolonged
OS. Smoking status was a negative independent prognostic factor in a multi-variate
analysis. The use of alectinib or lorlatinib in any treatment line improved overall outcome.
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INTRODUCTION
Over the past years, several key improvements in the treatment
of non-small cell lung cancer (NSCLC) have been made. In
particular, the identification of genetic alterations responsible for
initiation andmaintenance of the malignant phenotype in several
cancers including NSCLC has led to the development of targeted
therapies. These new molecules specifically target the so-called
oncogenic driver mutation and have improved patient outcomes,
in terms of overall survival (OS), but also in terms of quality of
life (QoL). Among different oncogenic driver mutations known
in NSCLC, rearrangements of the ALK (anaplastic lymphoma
kinase) gene have been a particularly successful target in terms of
the development of new targeted therapies, achieving important
improvements in survival (1–6). ALK gene rearrangements are
present in about 5% of NSCLC patients (7). They were first
identified in a resected adenocarcinoma specimen from a 62-
year-old male smoker, and can involve different fusion partners
presenting as either inversions or translocations (8, 9). Inversions
on the short arm of chromosome 2, which juxtapose echinoderm
microtubule-associated protein-like 4 (EML4) with ALK and
produce EML4-ALK-fusion proteins are the most commonly
observed rearrangement, but at least 27 fusion variants have been
identified so far (2, 10).
Identification of an ALK rearrangement is of therapeutic
relevance at the time of initiation of first-line treatment, as it
confers sensitivity to ALK tyrosine kinase inhibitors (ALK-TKIs).
Importantly, the rare occurrence of KRAS co-mutations leads to
primary resistance to ALK-TKIs (11). These targeted therapies
have resulted in major clinical advances over the last decade, with
superior objective response rates (ORRs) and progression-free
survival (PFS) compared to conventional chemotherapy in ALK
rearranged patients, initially shown for the first generation ALK-
TKI crizotinib (4, 12). Despite the initial efficacy of crizotinib,
patients progress after a median time of about 12 months,
with the brain being the most frequent site of progression
or relapse (13). This is due to the development of resistance
mechanisms, the most frequent one is the acquisition of point
mutations in the rearranged ALK gene. Classically, second-
generation ALK inhibitors such as alectinib or ceritinib have
emerged as standard of care in crizotinib-resistant patients
(14–17). Later, third-generation inhibitors such as lorlatinib
or the second-generation inhibitor brigatinib were shown to
overcome resistance to first and even second-generation ALK-
TKIs (18–21). However, each ALK-TKI has a different spectrum
of sensitivity to ALK-resistance mutations (22). In the light of
these findings, identifying the various resistance mechanisms
is becoming more important to select further treatments and
overcome acquired resistance (2).
Here, we report the results of the transalpine ALK registry, a
collaborative real-world study performed in five institutions in
Switzerland and one in Italy. The goal was to collect outcome
data of patients with ALK-rearranged NSCLC, with a particular
focus on overall survival (OS) by the use of ALK-TKIs and
their sequencing.
All the clinical ALK-rearranged NSCLC patients’ data were
retrospectively collected and analyzed. If available, biopsies both
before starting ALK-TKI and at progression were subjected to
next-generation sequencing (NGS) to further explore resistance
mechanisms. All this study was approved by the local ethics
committee (EK-ZH-2018-01919) and in accordance with the
local laws and regulations.
MATERIALS AND METHODS
Study Design
This is a retrospective study study performed in collaboration
among Swiss and Italian cancer centers. Data on patients with
metastatic ALK-rearranged NSCLC on treatment with an ALK-
TKI were collected by each participating center and assembled in
a central database.
Patients Characteristics
Several demographic and background clinical characteristics
were documented for each patient, such as age, gender, smoking
status, histology, patterns of metastases, co-mutations, and
treatments received in any line. Since the ALK-TKIs were utilized
in different lines of systemic treatment, the OS was calculated
from the date of diagnosis to the date of death or last time the
patient was seen. Patients still alive at the time of data collection
were censored at the date of the last available medical record.
Several other clinical endpoints were also assessed: objective
response rate (ORR) was defined as the proportion of patients
achieving either a complete or a partial remission as best clinical
response to an ALK-TKI according to the local radiologists’
interpretation based on the response Evaluation Criteria for Solid
Tumors (RECIST) 1.1 or clinically, when indicated. The ORR
rate, as well as the progression-free survival, were not reported
for the overall population due to the different treatment lines, in
which ALK-TKI were administered.
The inclusion criteria were as follows: diagnosed with
metastatic NSCLC, confirmation of an ALK gene rearrangement
by standard diagnostic procedures used in the respective
institution, as recorded in the patient’s medical record, 18 years of
age or older at diagnosis of ALK-rearranged NSCLC. If a biopsy
at diagnosis and at progression was available, those samples were
subjected to NGS.
Statistical Analyses
Descriptive statistics were used to summarize patients’
demographic and treatment characteristics at diagnosis and
subsequent recurrence or progression. All analyses were
conducted using SigmaPlot statistical software (Version 12.5;
San Jose, CA, USA). OS was analyzed using the Kaplan–Meier
method and was reported as median with confidence limits
(95% confidence intervals, CI), with statistical significance of
survival differences assessed using a non-parametric log-rank
test. In order to study any possible influence of main prognostic
factors on the OS, multivariate analysis was performed according
to the Cox proportional hazards survival model considering
statistically significant p < 0.05. All statistical analyses were
performed using two-sided tests. All data were analyzed for
the pooled study sample comprising patients from Italy and
Switzerland combined.
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Molecular Analysis
In four patients, pre- and post-treatment biopsies were subjected
to NGS using the Ion AmpliSeq Comprehensive Cancer Panel
(CCP), or the Thermo Fisher Oncomine Focus Assay Panel
(OFA). NGS was performed centrally at one of the sites
(University Hospital Zurich). The variant calling was done
using Ion Reporter (Thermo Fisher Scientific). Only variants
predicted to be damaging by SIFT and PolyPhen were included.
Additionally, the variant frequency cut-off was adjusted to the
estimated tumor cell content in each specimen.
RESULTS
Patient Characteristics
Between January 2011 and June 2016, a total of 121 patients
at six centers were identified. Break-apart fluorescence in
situ hybridization was used in almost all cases to detect
ALK rearrangement (n = 119). In the remaining two cases,
ALK immunohistochemistry was performed. Baseline patients’
characteristics are summarized in Table 1. Fifty-six were male
and 65 female, median age was 52 years old (range 19–81).
Histology was adenocarcinoma in 111 cases (92%). The majority
of the patients were never smokers (56%, 58 patients, out of 104
assessable patients). Of 121 patients, 98 presented with stage IV
disease (98/121; 92%), 37 (37/121; 31%) with brain metastases at
the time of diagnosis; additionally, 14 patients (14/84; 17%) newly
developed brain metastases under therapy. 115 received first-line
treatment with either chemotherapy (ChT) (n = 86, 71%), or
ALK-TKIs (n = 29, 24%). Seventy-five patients (62%) received
ALK-TKIs after first-line treatment, 58 (48%) as second-line
treatment. Forty-six patients (45%) receivedmore than one ALK-
TKI treatment line, including the use of alectinib or lorlatinib in
26 of them (25%). Seventeen patients (14%) have not received
a treatment with ALK-TKI at the time of analysis (of these
17 patients, 6 patients started with first line chemo and were
either still controlled/even in complete remission at censoring,
or were converted to be treated in an oligo-metastatic approach
and have never relapsed since then; eight patients have started
with first line chemo and have died before ever having had the
chance to get a TKI; form three patients only data on survival
were available).
Outcome
With a median follow-up of 39.5 months (95% confidence
interval [CI]: 32.1–77.7), median OS was 48.0 months (95%
CI: 12.9–83.0). A non-significant trend in OS was observed
between patients with or without brain metastases at diagnosis
(median OS 34.8 vs. 72.4 months, respectively, p = 0.323),
with no significant difference in OS between those treated or
not with brain radiotherapy (median OS not reached vs. 24.6
months, respectively, p = 0.567). No significant difference in
OS was observed between patients treated with ALK-TKIs or
ChT as first-line treatment (p = 0.955). A significant difference
in OS was observed in favor of patients treated with more
than one treatment line of ALK-TKIs as compared to those
treated only with one line of ALK-TKI (median OS of 85.7
TABLE 1 | Characteristics of patients (n = 121).
Parameter n (%)
Patients receiving TKI PatientswithoutTKI
104 17
Region of origin
Italy/Switzerland 42/62 (40/60) 1/16 (6/94)
Gender
Female/Male 55/49 (53/47) 10/7 (58/42)
Age, median 52 (19–81 year) 61 (36–79)
Tobacco
Never/former/current smokers 52/16/20 (50/15/19)a 6/8 (35/47)
Unknown 16 (15) 3 (18)
Histology
Adenocarcinoma 95 (91) 16 (94)
Squamous/others 9 (8) 1 (6)
Stage at diagnosis
I/II/III 3/2/15 (3/2/14) 0/2/1 (0/11/6)
IV 84 (81) 14 (82)
≥3 involved organs 46 (44) 5 (29)
BMs 33 (33)a 4 (23)
BMs treated with RT 24 (72)b 4 (100)
BMs new on treatment 13 (19)c 1 (8)
1st line CHT 75 (72) 11 (65)
1st line TKI 29 (24)
Crizotinib/alectinib/ceritinib 24/3/2 (83/10/7)
>1st line TKI 75 (62)
2nd/3rd/4th/5th/6th/8th line 58/9/3/2/2/1 (48/7/2/2/2/1)
One TKI line 57 (55)d
>One TKI line 46 (45)d
Use of alectinib/lorlatinib 26 (25)e
Use of crizotinib ± ceritinib 78 (75)e
No use of TKI 17 (14)
aOf 103 assessable patients.
bOf patients with BMs.
cOf patients without BMs at diagnosis.
dOf assessable patients.
eOf 103 assessable patients.
BMs, brain metastases; CHT, chemotherapy; CI, confidence interval; OS, overall survival;
RT, radiotherapy; TKI, tyrosine kinase inhibitor.
vs. 34.8 months, respectively, p = 0.016) and whose ALK-
TKIs included alectinib or lorlatinib (median OS of 85.7 vs.
37.3 months, respectively, p = 0.022; see Table 2 and Figure 1).
In multivariate analysis, never smoker status was the only
independent prognostic factor associated with better OS (Hazard
Ratio [HR] 0.499, 95% CI: 0.265–0.941, p = 0.032). A non-
significant trend toward a better prognosis was observed for
adenocarcinoma histology (HR 0.418, 95% CI: 0.175–1.002, p =
0.051; see Table 3).
Analysis of Resistance to ALK-TKIs
Case #1 was a male with a history of cisplatin/pemetrexed as a
first-line therapy, with disease stabilization for 6 months. Upon
progression, he was started on crizotinib with a partial remission
(PR) as best response, which lasted for 7 months. He was first
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OS no BMs 72.4 33.0–111.7 0.323
OS BMs 34.8 NA
Brain RT NR NA 0.567a
No brain RT 24.6 20.2–29.0
1st line TKI 35.8 16.9–54.7 0.526
>1st line TKI 72.4 29.3–115.4
1st line TKI 35.8 NA 0.955
1st line CHT 48.0 11.8–84.1
One TKI line 34.8 21.6–48,0 0.016
>One TKI line 85.7 63.9–107.5
Use of alectinib/lorlatinib 85.7 64.0–107.5 0.022
Use of crizotinib ± ceritinib 37.3 16.1–58.6
aOn 37 patients with BM only.
BMs, brain metastases; CHT, chemotherapy; CI, confidence interval; NA, not assessable;
NR, not reached; OS, overall survival; RT, radiotherapy; TKI, tyrosine kinase inhibitor.
oligo-progressing and received a pulmonary lobectomy of the left
lower lobe with continuation of crizotinib, but was switched to
docetaxel three months later upon systemic progression. After
two months he was progressing and switched to ceritinib for
5 months, but was then progressing in the brain. After that,
alectinib was initiated, which achieved a PR for almost 1.5 years.
He then progressed in the liver and a hepatic lesion was biopsied.
This biopsy and the lobectomy specimen were subjected to NGS
using the CCP and an ALK p.Ile1171Ser point mutation was
detected in the liver biopsy, which was absent before, most likely
explaining the resistance to alectinib (Figure 2).
Case #2 was a female patient who was diagnosed with
stage IIIA adenocarcinoma of the lung. She was operated
upfront and received an adjuvant chemotherapy with four
cycles of cisplatin/pemetrexed, but relapsed 7 months later with
metastases in retroclavicular lymph nodes. At that point, an ALK-
translocation was diagnosed and she was started on crizotinib.
Upon progression, she received cisplatin/pemetrexed again, later
a re-challenge, followed by docetaxel and then ceritinib. Upon
progression in the brain and liver she was started on lorlatinib.
After an initial response she was progressing in the liver and
in the bones. An NGS analysis performed on a biopsy of a
progressing hepatic lesion using the OFA panel at that stage
showed expression of the EGFR variant III with deletion of exons
2–7 (EGFRvIII, Figure 2). This EGFR variant has been discussed
to be potentially immunogenic and was assessed in clinical trials
in glioblastoma (23). The patient was started on nivolumab and
responded for 6 months.
Case #3 was a male patient with a stage IV (bone)
adenocarcinoma of the lung. After an initial course of palliative
cisplatin/pemetrexed he was started on crizotinib and was
responding for 14 months. He then presented with oligo-
progressive disease (oligo-PD) in two locations (bone), on which
he was irradiated while continuing crizotinib. However, 2months
later he was progressing in the primary tumor, which was
biopsied. The initial diagnostic specimen and this re-biopsy were
subjected to NGS using the CCP, which showed emergence of
a BCL9 p.Arg1401_Pro1402delinsThrAla mutation (Figure 2).
The primary tumor was then irradiated and the patient continued
on crizotinib for more than 1.5 years until he deceased suddenly
at home.
Case #4 was a female patient with stage IV (malignant
pleural effusion) adenocarcinoma of the lung. She received one
cycle of palliative cisplatin/pemetrexed, but due to side effects
and her reduced general condition was switched to crizotinib
shortly thereafter. She was progressing 7 months later, at which
timepoint a broncho-alveolar lavage (BAL) was performed. Cells
from this BAL and cells from the initial malignant pleural
effusion were subjected to NGS using the CCP, which showed
a newly emergent LPP p.Arg415Cys mutation. The patient was
then started on ceritinib with a partial remission as best response,
which was maintained for 6 months. She then deteriorated
rapidly and eventually died due to a pulmonary infection and
pulmonary PD.
DISCUSSION
Patients with ALK-fusion positive stage IV NSCLC represent a
subgroup with favorable OS compared to patients with NSCLC
and no actionable molecular alterations. Real-life data allow
for evaluating the impact of treatment sequences, as well as
giving detailed information about clinical features, which can be
associated with patients outcome. Here we present the analysis of
121 ALK-fusion-positive patients treated in several institutions
with comprehensive data and access to ALK-TKI through early
access programs and/or clinical trials with ALK-TKI. In this
cohort of ALK positive patients, the median OS was 48 months.
This reflects the impressive efforts made in the development and
access to ALK-TKIs when compared to NSCLC patients without
actionable molecular alterations. Since the very first results with
crizotinib in late and first-line, the treatment of these patients
has dramatically changed (2). However, OS survival from the
PROFILE-1014 differs based on the access to further ALK-TKI
after crizotinib, with a 5 year survival rate of 75 vs. 28% in
patients who received subsequent ALK-TKI or not, respectively
(4, 24). Indeed, also in our cohort of patients, the major impact
on survival was given by the access to subsequent ALK-TKIs
with patients receiving subsequent ALK-TKI having a median
OS of 85.7 vs. 34.8 months if they did not. These data closely
resemble previous observations by Pacheco et al. (25) reporting
a median overall survival of 80 months, where about 80% of
the patients received subsequent ALK-TKIs and 89.6 months
reported by Duruisseaux in patients receiving next-generation
ALK-TKIs compared to 28.2 months when they did not (26).
On the other hand a median OS of 49 months was reported by
Gainor, as 70% received only ceritinib as second line ALK-TKI
(17). Accessibility to drugs and performance status might play a
role in the patients who underwent subsequent treatment lines,
which is difficult to discriminate retrospectively.
We could not evaluate the impact of alectinib given in
first vs. further lines of therapy due to the small number of
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FIGURE 1 | OS curves (median follow-up of 39.5 months, 95% CI: 32.1–77.7). (A) OS of all patients, median 48.0 months (95% CI: 12.9–83.0). (B) OS according to
the first-line of treatment, first-line TKI median 35.8 months (95% CI NA) vs. first-line ChT 48.0 months (95% CI: 11.8–84.1) (p = 0.955). (C) OS according to the
number of lines of TKIs, >one line of TKIs median 85.7 months (95% CI: 63.9–107.5) vs. one line of TKI 34.8 months (95% CI: 21.6–48.0; p = 0.016). (D) OS
according to the use of alectinib or lorlatinib in any line. Alectinib/lorlatinib median 85.7 months (95% CI: 64.0–107.5) vs. crizotinib ± ceritinib 37.3 months (95% CI:
16.1–58.6; p = 0.022). ChT, chemotherapy; CI, confidence interval; NA, not assessable; No., number; OS, overall survival; TKI, tyrosine kinase inhibitor.
patients receiving it in first-line (n = 3). In order to identify
possible clinical features with impact on patients survival, we first
evaluated the localization pattern and number of metastases at
time of diagnosis. Clinical characteristics of this patient cohort
did not differ from the ones reported in clinical trials, e.g., brain
metastases were present in 30% of patients at time of diagnosis.
It has been previously reported that liver and multiple-organ
metastases might have a negative prognostic impact in patients
with advanced adenocarcinoma of the lung (27). In our ALK-
rearranged NSCLC cohort, however, the number or localizations
of metastases did not have any impact on survival. In line with
previous reports, the presence of brainmetastases in patients with
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TABLE 3 | Cox multivariate analysis on OS.
Parameter HR 95% CI p-value
Gender (female vs. male) 1.191 0.645-2.199 0.576
Tobacco (never vs. other) 0.499 0.265-0.941 0.032
Histology (adenocarcinoma vs. other) 0.418 0.175-1.002 0.051
Stage (IV vs. other) 2.187 0.860-5.563 0.100
Brain metastases (yes vs. no) 1.172 0.560-2453 0.673
Organ (3 or more vs. less) 1.653 0.795-3.437 0.178
CI, confidence interval; HR, Hazard Ratio; OS, overall survival.
ALK-fusion-positive NSCLC had no impact on patients outcome,
and neither did radiotherapy of brain metastases. Only a positive
smoking history was a significant prognostic factor for worse
survival. About 45% of patients were current or former smokers,
which underscores the importance of testing all patients for ALK
gene rearrangements, irrespective of their smoking status. ALK
testing was almost exclusively performed by FISH at time of
diagnosis, and in four cases the analysis of resistance mechanisms
to ALK-TKI was performed using a tissue biopsy. Molecular
analysis included NGS, which allowed the detection of ALK
mutations previously described to be associated with resistance
FIGURE 2 | Summary of molecular aberrations in pre- and post-treatment biopsies.
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to crizotinib and one patient with expression of an alternative
splice variant of EGFR (EGFRvIII). This is the first report
of such an alteration as a potential mechanism of resistance
to lorlatinib. The EGFRvIII splice variant has been reported
in solid tumors and has been reported to generate a highly
immunogenic peptide that is currently being studied as target
for immunotherapeutic approaches (23). In our patient, based on
this result, a treatment with an anti PD-1 antibody (nivolumab)
as monotherapy was initiated, leading to a partial response.
This is of major interest as ALK-fusion-positive patients are
usually excluded from clinical trials with immunotherapies due
to reported lack of responses (28, 29). This discovery underlines
the importance of detecting and understanding newmechanisms
of resistance in this population of patients.
Taken together, an analysis of real-world data allowed for
understanding the dynamics of tumor evolution in ALK-fusion-
positive patients under specific ALK-TKIs. Understanding the
resistance mechanisms that evolve during this treatment journey
for each patient is key toward the general aim of precision
medicine. In particular, access to further lines of ALK-TKIs
had a significant impact on survival of a broad population of
ALK-fusion-positive patients who represent every-day patients
seen in clinical practice. The transalpine registry has fostered
a collaborative effort between different institutions with the
intent to learn more from each single case, to give access to
drugs, and to search for resistance mechanisms to ALK-TKI; an
issue still under debate with newly discovered implications for
patients care.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by Zurich Ethical committee, (EK-ZH-2018-091919)
and all participants provided informed consent to participate in
this study. Written informed consent was obtained from every
patient for the publication of any potentially identifiable images
or data included in this manuscript.
AUTHOR CONTRIBUTIONS
All authors listed have made a substantial, direct and intellectual
contribution to the work, and approved it for publication.
REFERENCES
1. Ryser CO, Diebold J, Gautschi O. Treatment of anaplastic lymphoma kinase-
positive non-small cell lung cancer: update and perspectives.Curr Opin Oncol.
(2019) 31:8–12. doi: 10.1097/CCO.0000000000000494
2. Addeo A, Tabbo F, Robinson T, Buffoni L, Novello S. Precision medicine in
ALK rearranged NSCLC: a rapidly evolving scenario. Crit Rev Oncol Hematol.
(2018) 122:150–6. doi: 10.1016/j.critrevonc.2017.12.015
3. Camidge DR, Kim HR, AhnM-J, Yang JC-H, Han J-Y, Lee J-S, et al. Brigatinib
versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med.
(2018) 379:2027–39. doi: 10.1056/NEJMoa1810171
4. Solomon BJ, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, et al. Final
overall survival analysis from a study comparing first-line crizotinib versus
chemotherapy in ALK-mutation-positive non-small-cell lung cancer. J Clin
Oncol. (2018) 36:2251–8. doi: 10.1200/JCO.2017.77.4794
5. Soria JC, Tan DS, Chiari R, Wu YL, Paz-Ares L, Wolf J, et al. First-line
ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged
non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3
study. Lancet. (2017) 389:917–29. doi: 10.1016/S0140-6736(17)30123-X
6. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib
versus crizotinib in untreated ALK-positive non-small-cell lung cancer.NEngl
J Med. (2017) 377:829–38. doi: 10.1056/NEJMoa1704795
7. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist
RS, et al. Clinical features and outcome of patients with non-small-
cell lung cancer who harbor EML4-ALK. J Clin Oncol. (2009) 27:4247–
53. doi: 10.1200/JCO.2009.22.6993
8. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al.
Identification of the transforming EML4-ALK fusion gene in non-small-cell
lung cancer. Nature. (2007) 448:561–6. doi: 10.1038/nature05945
9. Ou SH, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ. Crizotinib for
the treatment of ALK-rearranged non-small cell lung cancer: a success story
to usher in the second decade of molecular targeted therapy in oncology.
Oncologist. (2012) 17:1351–75. doi: 10.1634/theoncologist.2012-0311
10. Sasaki T, Rodig SJ, Chirieac LR, Janne PA. The biology and treatment
of EML4-ALK non-small cell lung cancer. Eur J Cancer. (2010) 46:1773–
80. doi: 10.1016/j.ejca.2010.04.002
11. Schmid S, Gautschi O, Rothschild S, Mark M, Froesch P, Klingbiel
D, et al. Clinical outcome of ALK-positive non-small cell lung
cancer (NSCLC) patients with de novo EGFR or KRAS co-mutations
receiving tyrosine kinase inhibitors (TKIs). J Thorac Oncol. (2017)
12:681–8. doi: 10.1016/j.jtho.2016.12.003
12. Shaw AT, Kim D-W, Nakagawa K, Seto T, Crinó L, Ahn M-J, et al. Crizotinib
versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med.
(2013) 368:2385–94. doi: 10.1056/NEJMoa1214886
13. Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, et al. Clinical
experience with crizotinib in patients with advanced ALK-rearranged non-
small-cell lung cancer and brain metastases. J Clin Oncol. (2015) 33:1881–
8. doi: 10.1200/JCO.2014.59.0539
14. Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, et al. Alectinib
in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase
II global study. J Clin Oncol. (2016) 34:661–8. doi: 10.1200/JCO.2015.63.9443
15. Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, et al.
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer:
a single-group, multicentre, phase 2 trial. Lancet Oncol. (2016) 17:234–
42. doi: 10.1016/S1470-2045(15)00488-X
16. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, et al. Ceritinib in
ALK-rearranged non-small-cell lung cancer. N Engl J Med. (2014) 370:1189–
97. doi: 10.1056/NEJMoa1311107
17. Gainor JF, Tan DS, De Pas T, Solomon BJ, Ahmad A, Lazzari C, et al.
Progression-free and overall survival in ALK-positive NSCLC patients treated
with sequential crizotinib and ceritinib. Clin Cancer Res. (2015) 21:2745–
52. doi: 10.1158/1078-0432.CCR-14-3009
18. Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, et al.
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer
and othermalignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol.
(2016) 17:1683–96. doi: 10.1016/S1470-2045(16)30392-8
19. Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, et al.
Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-
positive non-small-cell lung cancer: a randomized, multicenter phase II trial.
J Clin Oncol. (2017) 35:2490–8. doi: 10.1200/JCO.2016.71.5904
20. Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, et al.
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an
international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Lancet Oncol. (2017) 18:1590–9. doi: 10.1016/S1470-2045(17)30680-0
21. Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR,
et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer:
results from a global phase 2 study. Lancet Oncol. (2018) 19:1654–
67. doi: 10.1016/S1470-2045(18)30649-1
22. Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R,
et al. Molecular mechanisms of resistance to first- and second-generation
ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. (2016)
69:S138. doi: 10.1016/S0959-8049(16)33009-X
Frontiers in Oncology | www.frontiersin.org 7 August 2020 | Volume 10 | Article 1299
Britschgi et al. Real-World NSCLC ALK Data
23. Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, et al.
Rindopepimut with temozolomide for patients with newly diagnosed,
EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-
blind, international phase 3 trial. Lancet Oncol. (2017) 18:1373–85.
doi: 10.1016/S1470-2045(17)30517-X
24. Friedlaender A, Banna G, Patel S, Addeo A. Diagnosis and treatment of
ALK aberrations in metastatic NSCLC. Curr Treat Options Oncol. (2019)
20:79. doi: 10.1007/s11864-019-0675-9
25. Pacheco JM, Gao D, Smith D, Purcell T, Hancock M, Bunn P, et al.
Natural history and factors associated with overall survival in stage IV
ALK-rearranged non-small cell lung cancer. J Thorac Oncol. (2019) 14:691–
700. doi: 10.1016/j.jtho.2018.12.014
26. Duruisseaux M, Besse B, Cadranel J, Perol M, Mennecier B, Bigay-Game L,
et al. Overall survival with crizotinib and next-generation ALK inhibitors
in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a
French nationwide cohort retrospective study. Oncotarget. (2017) 8:21903–
17. doi: 10.18632/oncotarget.15746
27. Ren Y, Dai C, Zheng H, Zhou F, She Y, Jiang G, et al. Prognostic effect of liver
metastasis in lung cancer patients with distant metastasis. Oncotarget. (2016)
7:53245–53. doi: 10.18632/oncotarget.10644
28. Garassino MC, Cho BC, Kim JH, Mazieres J, Vansteenkiste J, Lena H, et al.
Durvalumab as third-line or later treatment for advanced non-small-cell lung
cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol.
(2018) 19:521–36. doi: 10.1016/S1470-2045(18)30144-X
29. Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, et al. EGFR
mutations and ALK rearrangements are associated with low response rates to
PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis.
Clin Cancer Res. (2016) 22:4585–93. doi: 10.1158/1078-0432.CCR-15-3101
Conflict of Interest: CB reports personal fees from AstraZeneca, Pfizer, Takeda,
Roche, Janssen-Cilag, Novartis and Boehringer-Ingelheim; non-financial support
fromAstraZeneca and Takeda; all outside the submitted work. AA reports personal
fees from AstraZeneca, Pfizer, Takeda, Roche, Takeda, MSD, and BMS; grants
and personal fees from Boehringer-Ingelheim; all outside the submitted work.
RD reports personal fees from Janssen-Cilag, Boehringer-Ingelheim, and IPSEN
pharma, outside the submitted work. MF reports grants and other from BMS;
other from BMS, MSD, Astra Zeneca, Boehringer-Ingelheim, Roche, and Takeda;
grants from Astra Zeneca; all outside the submitted work. GM reports personal
fees from Boehringer-Ingelheim and non-financial support from AstraZeneca,
outside the submitted work. SR reports grants, non-financial support and other
from AstraZeneca, Roche, and Boehringer-Ingelheim; personal fees, non-financial
support and other from Takeda; non-financial support, and other from MSD
Oncology and Bristol-Myers-Squibb; other from Pfizer, Novartis, Eli Lilly, Eisai;
grants and other fromMeck Serono; grants from AbbVie; all outside the submitted
work. PW reports personal fees from AstraZeneca, Pfizer, Takeda, Roche Janssen-
Cilag, Novartis, and Boehringer-Ingelheim, outside the submitted work. GB
reports personal fees from Janssen-Cilag, Boehringer Ingelheim, and Roche;
non-financial support from Bristol-Myers Squibb, AstraZeneca/MedImmune,
Pierre Fabre, and Ipsen; all outside the submitted work. AC-F reports personal
fees from Astra Zeneca, Roche, Pfizer, Takeda, BMS, Boehringer Ingelheim, and
MSD, outside the submitted work.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2020 Britschgi, Addeo, Rechsteiner, Delaloye, Früh, Metro, Banini,
Gautschi, Rothschild, Wild, Banna and Curioni-Fontecedro. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Oncology | www.frontiersin.org 8 August 2020 | Volume 10 | Article 1299
